Interpace Biosciences amends 8-K to disclose adoption of 2026 equity incentive, employee stock purchase plans
IDXG•Amended 8-K adds disclosure of new benefit plans
Interpace Biosciences filed an amended Form 8-K to correct its Aug. 20, 2026 report by adding disclosure of new benefit plans.
The amendment confirms stockholder adoption of a 2026 Equity Incentive Plan, replacing the 2019 Equity Incentive Plan.
It also confirms adoption of a 2026 Employee Stock Purchase Plan, replacing the 2019 Employee Stock Purchase Plan.
No further equity grants will be made under the 2019 plan. No further purchases will be allowed under the 2019 ESPP.
